Search results
Results from the WOW.Com Content Network
The market data for a particular instrument would include the identifier of the instrument and where it was traded such as the ticker symbol and exchange code plus the latest bid and ask price and the time of the last trade. It may also include other information such as volume traded, bid, and offer sizes and static data about the financial ...
Diagnosis dates are listed where the information is known. Breast cancer is the second most common cancer in women after skin cancer. According to the United States National Cancer Institute, the rate of new cases of female breast cancer was 129.1 per 100,000 women per year. The death rate was 19.9 per 100,000 women per year.
The bid–ask spread (also bid–offer or bid/ask and buy/sell in the case of a market maker) is the difference between the prices quoted (either by a single market maker or in a limit order book) for an immediate sale and an immediate purchase for stocks, futures contracts, options, or currency pairs in some auction scenario.
On Wednesday, BriaCell Therapeutics (NASDAQ:BCTX) stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.
On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering of $150 million. The company also announced updated Phase 1b data on ...
Also Read: Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday – Here’s Why. The company earlier reported that patients #1 and #2 in Cohort A achieved overall survival ...
For instance, if a trader submits a limit order to buy 1,000 shares of MSFT at $28.00, this order will appear in a market maker for MSFT's book with a bid of $28.00 and a bid size of 1000. The difference between the bid and ask price is known as the bid–ask spread.
Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb ...